Abstract
Hereditary angioedema (HAE) is a rare genetic disease causing repeated swellings that can be life-threatening. HAE is caused by excessive bradykinin and neurokinin due to a deficient or defective serine protease inhibitor, plasma-derived C1 esterase inhibitor (pdC1-INH). Pharmacotherapy has significantly improved with the development of medications targeting the kinin pathway to prevent and reduce the duration and severity of attacks. Pharmacists’ understanding of these new drugs will ensure that medications are appropriately used and patient outcomes improved.
| Original language | English |
|---|---|
| Pages | HS17-HS21 |
| Volume | 40 |
| No | 10 |
| Specialist publication | U.S. Pharmacist |
| State | Published - Oct 16 2015 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmaceutical Science
- Pharmacology
- Pharmacy
Cite this
Advances in the pharmacotherapy of hereditary angioedema. / Cotiguala, Laura M.; Coover, Kelli L.; Bewtra, Againdra K.; Malesker, Mark A.
In: U.S. Pharmacist, Vol. 40, No. 10, 16.10.2015, p. HS17-HS21.Research output: Contribution to specialist publication › Article
}
TY - GEN
T1 - Advances in the pharmacotherapy of hereditary angioedema
AU - Cotiguala, Laura M.
AU - Coover, Kelli L.
AU - Bewtra, Againdra K.
AU - Malesker, Mark A.
PY - 2015/10/16
Y1 - 2015/10/16
N2 - Hereditary angioedema (HAE) is a rare genetic disease causing repeated swellings that can be life-threatening. HAE is caused by excessive bradykinin and neurokinin due to a deficient or defective serine protease inhibitor, plasma-derived C1 esterase inhibitor (pdC1-INH). Pharmacotherapy has significantly improved with the development of medications targeting the kinin pathway to prevent and reduce the duration and severity of attacks. Pharmacists’ understanding of these new drugs will ensure that medications are appropriately used and patient outcomes improved.
AB - Hereditary angioedema (HAE) is a rare genetic disease causing repeated swellings that can be life-threatening. HAE is caused by excessive bradykinin and neurokinin due to a deficient or defective serine protease inhibitor, plasma-derived C1 esterase inhibitor (pdC1-INH). Pharmacotherapy has significantly improved with the development of medications targeting the kinin pathway to prevent and reduce the duration and severity of attacks. Pharmacists’ understanding of these new drugs will ensure that medications are appropriately used and patient outcomes improved.
UR - http://www.scopus.com/inward/record.url?scp=84944453594&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944453594&partnerID=8YFLogxK
M3 - Article
VL - 40
SP - HS17-HS21
JO - U.S. Pharmacist
JF - U.S. Pharmacist
SN - 0148-4818
ER -